© 2023 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
© 2023 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Esteemed medical oncologist Matthew Galsky, MD, discusses the case of a 55-year-old man with muscle-invasive bladder cancer (MIBC) and reviews the options for treatment in the adjuvant setting.
January 23rd 2023
Matthew Galsky, MD, presents the case of a 55-year-old man with stage T2N0M0 muscle-invasive bladder cancer (MIBC) for review, and explains how cisplatin eligibility is defined in patients.
Dr Matthew Galsky reviews the available adjuvant therapy options for patients with stage II or III MIBC who previously underwent bladder removal surgery.
Matthew Galsky, MD, explains safety and efficacy data from the CheckMate 274 trial, which led to the FDA approval of adjuvant nivolumab for patients with MIBC, and highlights important data updates from recent conferences.
Dr Matthew Galsky explains the adjuvant therapy regimen he would have recommended for the patient with MIBC from the presented case, and whether patient preference factors into his decisions in clinical practice.
Matthew Galsky, MD, highlights some remaining unmet needs for patients with MIBC, and currently ongoing clinical trials in the neoadjuvant MIBC treatment setting that excite him.
Dr Matthew Galsky contemplates how he would use immunotherapy in patients with MIBC, if it were available for use in both the neoadjuvant and adjuvant setting.